TWI831325B - 作為atr抑制劑的萘啶衍生物及其製備方法 - Google Patents

作為atr抑制劑的萘啶衍生物及其製備方法 Download PDF

Info

Publication number
TWI831325B
TWI831325B TW111130300A TW111130300A TWI831325B TW I831325 B TWI831325 B TW I831325B TW 111130300 A TW111130300 A TW 111130300A TW 111130300 A TW111130300 A TW 111130300A TW I831325 B TWI831325 B TW I831325B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
general formula
group
compounds
Prior art date
Application number
TW111130300A
Other languages
English (en)
Chinese (zh)
Other versions
TW202306955A (zh
Inventor
謝雨禮
劉文中
錢立暉
Original Assignee
大陸商微境生物醫藥科技(上海)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商微境生物醫藥科技(上海)有限公司 filed Critical 大陸商微境生物醫藥科技(上海)有限公司
Publication of TW202306955A publication Critical patent/TW202306955A/zh
Application granted granted Critical
Publication of TWI831325B publication Critical patent/TWI831325B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW111130300A 2021-08-11 2022-08-11 作為atr抑制劑的萘啶衍生物及其製備方法 TWI831325B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202110919812.6 2021-08-11
CN202110919812 2021-08-11
CN202111188963.5 2021-10-12
CN202111188963 2021-10-12
CN202210918443.3 2022-08-01
CN202210918443 2022-08-01

Publications (2)

Publication Number Publication Date
TW202306955A TW202306955A (zh) 2023-02-16
TWI831325B true TWI831325B (zh) 2024-02-01

Family

ID=85199870

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111130300A TWI831325B (zh) 2021-08-11 2022-08-11 作為atr抑制劑的萘啶衍生物及其製備方法

Country Status (8)

Country Link
US (1) US20240317741A1 (https=)
EP (1) EP4385992A4 (https=)
JP (1) JP2024529070A (https=)
CN (1) CN117642401A (https=)
AU (1) AU2022325376A1 (https=)
CA (1) CA3227336A1 (https=)
TW (1) TWI831325B (https=)
WO (1) WO2023016529A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795156A (zh) * 2014-08-04 2017-05-31 拜耳制药股份公司 2‑(吗啉‑4‑基)‑1，7‑萘啶
CN108699057A (zh) * 2016-01-14 2018-10-23 拜耳医药股份公司 5-取代的2-(吗啉-4-基)-1,7-萘啶

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018153970A1 (en) * 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine
AU2019373416A1 (en) * 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
US20240043419A1 (en) * 2020-09-27 2024-02-08 Medshine Discovery Inc. Class of 1,7-naphthyridine compounds and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795156A (zh) * 2014-08-04 2017-05-31 拜耳制药股份公司 2‑(吗啉‑4‑基)‑1，7‑萘啶
CN108699057A (zh) * 2016-01-14 2018-10-23 拜耳医药股份公司 5-取代的2-(吗啉-4-基)-1,7-萘啶

Also Published As

Publication number Publication date
US20240317741A1 (en) 2024-09-26
WO2023016529A1 (zh) 2023-02-16
JP2024529070A (ja) 2024-08-01
EP4385992A1 (en) 2024-06-19
EP4385992A4 (en) 2025-12-03
TW202306955A (zh) 2023-02-16
CN117642401A (zh) 2024-03-01
CA3227336A1 (en) 2023-02-16
AU2022325376A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
TWI831325B (zh) 作為atr抑制劑的萘啶衍生物及其製備方法
JP7773987B2 (ja) スピロ環含有キナゾリン化合物
CN113767103B (zh) 新型螺环类K-Ras G12C抑制剂
JP7627974B2 (ja) Ｃｄｋ７キナーゼ阻害剤として使用される化合物およびその適用
WO2021129824A1 (zh) 新型K-Ras G12C抑制剂
WO2020259432A1 (zh) Kras-g12c抑制剂
CN109476635B (zh) 用于治疗疾病的二取代吡唑类化合物
WO2025045106A1 (zh) 一种PI3Kα抑制剂及其用途
CN105646389A (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
CN113164475A (zh) Dyrk1a的大环抑制剂
WO2020156189A1 (zh) 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途
CN117645604A (zh) 用作cdk4激酶抑制剂的化合物及其应用
TW201643143A (zh) 抑制氧化壓迫引發的神經細胞死亡之化合物
WO2021254384A1 (zh) 新型吡啶并[2，3-d]嘧啶-7(8H)-酮衍生物
TWI823255B (zh) 作為Wee-1抑制劑的稠環化合物
CN116390728A (zh) 喹唑啉衍生物及其制备方法和用途
WO2022012593A1 (zh) 5，6-二氢吡嗪并[2，3-c]异喹啉化合物
BR112021012428A2 (pt) Derivado de dihidropirazolopirazinona tendo atividade inibitória de mgat2
WO2025092773A1 (zh) 作为myt1抑制剂的化合物
WO2021047555A1 (zh) 芳香杂环衍生物作为免疫调节剂的制备及其应用
CN113880804A (zh) 新型苯并咪唑化合物
WO2024235218A1 (zh) Hdac1/2选择性抑制剂及其用途
CN119998274A (zh) Ulk抑制剂
WO2024104435A1 (zh) 三并环类PI3Kα抑制剂及其制备方法和医药用途
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物